CN102219729A - 光学纯的1,4-二氢-2,6-二甲基-4-(3-硝基苯)3,5-吡啶二羧酸 2-[(3,3-二苯基丙基)甲胺基]-1,1-二甲基甲酯的制备方法 - Google Patents
光学纯的1,4-二氢-2,6-二甲基-4-(3-硝基苯)3,5-吡啶二羧酸 2-[(3,3-二苯基丙基)甲胺基]-1,1-二甲基甲酯的制备方法 Download PDFInfo
- Publication number
- CN102219729A CN102219729A CN201110092001XA CN201110092001A CN102219729A CN 102219729 A CN102219729 A CN 102219729A CN 201110092001X A CN201110092001X A CN 201110092001XA CN 201110092001 A CN201110092001 A CN 201110092001A CN 102219729 A CN102219729 A CN 102219729A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- tartaric acid
- solid
- acid derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3,3-diphenylpropyl Chemical group 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 13
- MPFLRYZEEAQMLQ-UHFFFAOYSA-N dinicotinic acid Chemical compound OC(=O)C1=CN=CC(C(O)=O)=C1 MPFLRYZEEAQMLQ-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 117
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 76
- 239000007787 solid Substances 0.000 claims description 56
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 54
- 239000012452 mother liquor Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- 150000003892 tartrate salts Chemical class 0.000 claims description 16
- 230000007062 hydrolysis Effects 0.000 claims description 15
- 238000006460 hydrolysis reaction Methods 0.000 claims description 15
- 230000006340 racemization Effects 0.000 claims description 14
- 229940095064 tartrate Drugs 0.000 claims description 13
- 238000001953 recrystallisation Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims description 5
- YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- OOKSMYZBWRKRGU-UHFFFAOYSA-N 2-benzoyl-2,3-dihydroxybutanedioic acid Chemical class OC(=O)C(O)C(O)(C(O)=O)C(=O)C1=CC=CC=C1 OOKSMYZBWRKRGU-UHFFFAOYSA-N 0.000 claims description 3
- 239000004305 biphenyl Substances 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- OCQAXYHNMWVLRH-UHFFFAOYSA-N 2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical class C=1C=CC=CC=1C(=O)C(O)(C(O)=O)C(O)(C(=O)O)C(=O)C1=CC=CC=C1 OCQAXYHNMWVLRH-UHFFFAOYSA-N 0.000 claims 4
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229960004294 lercanidipine Drugs 0.000 abstract description 13
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 4
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 150000003899 tartaric acid esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 description 38
- 238000001035 drying Methods 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000005194 fractionation Methods 0.000 description 9
- 239000012458 free base Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- PTAPBGKYBVWNJY-UHFFFAOYSA-N 2,3-dibenzoyl-2,3-dihydroxybutanedioic acid;hydrate Chemical compound O.C=1C=CC=CC=1C(=O)C(O)(C(O)=O)C(O)(C(=O)O)C(=O)C1=CC=CC=C1 PTAPBGKYBVWNJY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229950007556 aranidipine Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical group C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960002162 lercanidipine hydrochloride Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110092001XA CN102219729B (zh) | 2011-04-13 | 2011-04-13 | 光学纯的1,4-二氢-2,6-二甲基-4-(3-硝基苯)3,5-吡啶二羧酸 2-[(3,3-二苯基丙基)甲胺基]-1,1-二甲基甲酯的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110092001XA CN102219729B (zh) | 2011-04-13 | 2011-04-13 | 光学纯的1,4-二氢-2,6-二甲基-4-(3-硝基苯)3,5-吡啶二羧酸 2-[(3,3-二苯基丙基)甲胺基]-1,1-二甲基甲酯的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102219729A true CN102219729A (zh) | 2011-10-19 |
CN102219729B CN102219729B (zh) | 2013-02-13 |
Family
ID=44776462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110092001XA Active CN102219729B (zh) | 2011-04-13 | 2011-04-13 | 光学纯的1,4-二氢-2,6-二甲基-4-(3-硝基苯)3,5-吡啶二羧酸 2-[(3,3-二苯基丙基)甲胺基]-1,1-二甲基甲酯的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102219729B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103497145A (zh) * | 2013-10-10 | 2014-01-08 | 南昌大学 | 一种光学纯多奈哌齐的制备工艺 |
CN105439942A (zh) * | 2015-12-02 | 2016-03-30 | 扬子江药业集团北京海燕药业有限公司 | 一种(s)-马尼地平的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101798280A (zh) * | 2010-03-22 | 2010-08-11 | 河北师范大学 | 一种手性拆分消旋体氨氯地平制备s-(-)-氨氯地平和r-(+)-氨氯地平的方法 |
-
2011
- 2011-04-13 CN CN201110092001XA patent/CN102219729B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101798280A (zh) * | 2010-03-22 | 2010-08-11 | 河北师范大学 | 一种手性拆分消旋体氨氯地平制备s-(-)-氨氯地平和r-(+)-氨氯地平的方法 |
Non-Patent Citations (1)
Title |
---|
《中国新药杂志》 20081231 韩艳淑等 乐卡地平合成的研究进展 114-118 1-9 第17卷, 第2期 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103497145A (zh) * | 2013-10-10 | 2014-01-08 | 南昌大学 | 一种光学纯多奈哌齐的制备工艺 |
CN103497145B (zh) * | 2013-10-10 | 2016-01-27 | 南昌大学 | 一种光学纯多奈哌齐的制备工艺 |
CN105439942A (zh) * | 2015-12-02 | 2016-03-30 | 扬子江药业集团北京海燕药业有限公司 | 一种(s)-马尼地平的制备方法 |
CN105439942B (zh) * | 2015-12-02 | 2018-12-18 | 扬子江药业集团北京海燕药业有限公司 | 一种(s)-马尼地平的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102219729B (zh) | 2013-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8198485B2 (en) | Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane | |
CN107805205A (zh) | 一种(r)‑3‑氨基丁醇的制备方法 | |
WO2006043148A1 (en) | Process for producing enantiomer of amlodipine in high optical purity | |
EP2681186B1 (en) | Process of resolution of 1-aminoindan | |
CN102219729B (zh) | 光学纯的1,4-二氢-2,6-二甲基-4-(3-硝基苯)3,5-吡啶二羧酸 2-[(3,3-二苯基丙基)甲胺基]-1,1-二甲基甲酯的制备方法 | |
CN100364976C (zh) | S-(-)-氨氯地平的制备方法 | |
WO2016038422A1 (en) | Process for the preparation of optically enriched adrenaline | |
CN103896826B (zh) | 氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法 | |
CN108409731B (zh) | 芳基取代的1H-吡啶[3,4-b]吲哚-3-羧酸甲酯的手性拆分 | |
CN101570506A (zh) | 一种新的制备手性氨氯地平的方法 | |
WO2012143801A1 (en) | Manufacturing process for tadalafil from racemic or l-tryptophan | |
WO2016157065A2 (en) | A process for preparation of dexmethylphenidate hydrochloride | |
CN101357901B (zh) | 手性1,4-二氢-4-(3-硝基苯基)-3,5-吡啶二羧酸酯及其制备方法与其制备药物的应用 | |
CA2674451C (en) | Process of enantiomeric resolution of d,l-(.plusminus.)-threo-methylphenidate | |
ITMI991731A1 (it) | Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine | |
JP2002537394A (ja) | パロキセチンの製造方法 | |
CN103012264A (zh) | 3-取代氨基-六氢-1h-氮杂环庚烷的拆分方法 | |
CN1442407A (zh) | 光学纯的非索非那定及其盐酸盐的化学拆分制备法 | |
KR20100022272A (ko) | 신규한 s-(-)-암로디핀 제조방법 | |
CN111763150B (zh) | 一种手性盐酸舍曲林的制备方法 | |
WO2005054196A1 (fr) | Methode de separation enantiomere d'une amlodipine active optique | |
WO2016116607A1 (en) | Process and intermediates for the racemization of enantiomerically enriched 1-aminoindane | |
JP3795550B2 (ja) | 光学的に純粋な1,4−ジヒドロピリジンの製造方法 | |
KR20030047466A (ko) | 라세미 피페리딘 카르복시산 유도체의 광학분할 방법 | |
KR101233139B1 (ko) | 라세믹 1,4-티아제핀 화합물의 분할 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for preparing optically pure 1,4- two hydrogen -2,6- two methyl -4- (3- nitrobenzene) 3,5- pyridine two carboxylic acid 2-[(3,3- two phenyl propyl) methylamine group]-1,1- two methyl ester Effective date of registration: 20160906 Granted publication date: 20130213 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2016340000050 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180612 Granted publication date: 20130213 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2016340000050 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of optically pure 1,4- two hydrogen -2,6- two methyl -4- (3- nitrobenzene) 3,5- pyridine two carboxylic acid 2-[(3,3- two phenyl propyl) methylamine]-1,1- two methyl methyl ester Effective date of registration: 20180622 Granted publication date: 20130213 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018340000247 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of optically pure 1,4-dihydro-2,6-dimethyl-4 - (3-nitrobenzene) 3,5-pyridinedicarboxylic acid 2 - [(3,3-diphenylpropyl) methylamino] - 1,1-dimethyl methyl ester Effective date of registration: 20200622 Granted publication date: 20130213 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003313 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200604 Granted publication date: 20130213 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018340000247 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211229 Granted publication date: 20130213 Pledgee: Agricultural Bank of China Limited by Share Ltd. Linquan county subbranch Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003313 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of optically pure 1,4-dihydro-2,6-dimethyl-4 - (3-nitrobenzene) 3,5-pyridine dicarboxylic acid 2 - [(3,3-diphenylpropyl) methylamino] - 1,1-dimethyl methyl ester Effective date of registration: 20211230 Granted publication date: 20130213 Pledgee: Anhui Linquan rural commercial bank Limited by Share Ltd. Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980017339 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230613 Granted publication date: 20130213 Pledgee: Anhui Linquan rural commercial bank Limited by Share Ltd. Pledgor: ANHUI YONGSHENGTANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980017339 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |